# CLOVER-WaM (NCT02952508)

> Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02952508
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Cellectar Biosciences, Inc.
- Conditions: Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma
- Interventions: Iopofosine I 131 single dose; Iopofosine I 131 multiple dose; Iopofosine I 131 fractionated dose
- Enrollment: 120
- Primary outcome: Part A [CLOVER-1] Clinical benefit rate
- Primary outcome: Part B [CLOVER-WaM] Major Response Rate

## Commentary we found

- YouTube: 2
- Podcasts: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=clover-wam-nct02952508